Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > BUSINESS
BUSINESS
- Bayer HealthCare Files Eylea for mCNV in Japan
December 4, 2013
- Reimbursement Listing of Ipragliflozin Expected in April; 4 Rival SGLT-2 Inhibitors Seen to Follow Suit 1 Month Later
December 3, 2013
- Takeda Ready to Welcome Foreign Exec with Open Arms as Company Leader
December 3, 2013
- Japan Gardasil Sales Dive 49.6% in January-September
December 3, 2013
- Merck to Shed 200 Jobs in Japan by 2015
December 3, 2013
- Eisai to Offer Voluntary Retirement Program in Japan
December 3, 2013
- Takeda President Calls GSK Weber Competitive Global Talent, Pushes Globalization
December 2, 2013
- Eisai Files for Approval of Pariet for Preventing Recurrent Ulcers during Aspirin Therapy
December 2, 2013
- GSK Exec Tapped as Takeda’s Next President, 1st Non-Japanese to Lead Japan Juggernaut
December 2, 2013
- AnGes MG to Resume Collategene Development for Critical Limb Ischemia Treatment: President Yamada
November 29, 2013
- No Mortality Cases Reported in Association with Eliquis at PMS: BMKK/Pfizer Japan
November 29, 2013
- MRs, Marketing Division Collaborate to Create Promotional Materials as Part of Pfizer Japan’s New Training Program
November 29, 2013
- President Hasegawa of Takeda Confident About Achieving Targets in Midterm Growth Strategy; Company to Appoint CIO
November 28, 2013
- Teva Japan Pres. Kikushige to Double as Head of Taisho Pharma
November 28, 2013
- Teva Pharma Japan to Temporarily Suspend Supply of Elsamet Combination Tablets
November 28, 2013
- Azilva Tops Physician “Mind Share” Ranking in GP, HP Markets in October: New Survey
November 27, 2013
- Sanofi to Revamp Sales Organization, 5 Units to Come Under Direct Control of President
November 27, 2013
- Santen’s Anti-Allergic Eye Drops Alesion Goes on Sale
November 27, 2013
- Eisai to Take Over Marketing Rights for Gliadel from Nobelpharma
November 27, 2013
- CHMP Recommends Approval of Otsuka’s Delamanid for Treatment of MDR-TB
November 27, 2013
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…